Brief: Arrowhead Pharmaceuticals - Licenses Aro-Pnpla3 To Madrigal Pharmaceuticals
05/05/2026 13:14
May 5 (Reuters) - Arrowhead Pharmaceuticals Inc ARWR.O: ARROWHEAD PHARMACEUTICALS - LICENSES ARO-PNPLA3 TO MADRIGAL PHARMACEUTICALS ARROWHEAD PHARMACEUTICALS - MADRIGAL TO PAY $25 MILLION UPFRONT AND UP TO $975 MILLION IN MILESTONES TO ARROWHEAD ARROWHEAD PHARMACEUTICALS - ELIGIBLE FOR TIERED ROYALTIES ON COMMERCIAL SALES Source text: ID:nBw68zVy9a Further company coverage: ARWR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arrowhead Pharmaceuticals
See all newsBrief: Uk's MHRA Authorises Redemplo For Adults With Familial Chylomicronaemia Syndrome
US STOCKS ON THE MOVE-Netflix, Coinbase Global, Accenture
US STOCKS ON THE MOVE-Bending Spoons, Skydance, Albertsons
US STOCKS ON THE MOVE-Albertsons, GlobalFoundries, American Electric Power, Fastenal
Brief: Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers